Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8020872rdf:typepubmed:Citationlld:pubmed
pubmed-article:8020872lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:8020872lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:8020872lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:8020872lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:8020872lifeskim:mentionsumls-concept:C0070915lld:lifeskim
pubmed-article:8020872lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:8020872pubmed:issue2lld:pubmed
pubmed-article:8020872pubmed:dateCreated1994-8-1lld:pubmed
pubmed-article:8020872pubmed:abstractTextThe structure activity relationship of phosphoramidon analogues was studied for their ability to reduce the hypertensive effect of exogenous proET-1, probably via inhibition of an endothelin converting enzyme activity (ECE). Results concerning in vivo ECE and in vitro thermolysin inhibitions were compared. In contrast to the phosphoryl group of phosphoramidon, which was found to be an absolute requirement, the rhamnose moiety was of very little importance for the inhibition of either enzyme. Furthermore, the tryptophan residue of phosphoramidon appeared to be particularly important for the ECE inhibition, whereas thermolysin inhibition seemed to depend greatly on the leucine residue. It is concluded that in vivo ECE and thermolysin differ in the way they recognise phosphoramidon. The existence of an hydrophobic pocket, specific for the recognition of the tryptophan residue of phosphoramidon, could be proposed for ECE.lld:pubmed
pubmed-article:8020872pubmed:languageenglld:pubmed
pubmed-article:8020872pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:citationSubsetIMlld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8020872pubmed:statusMEDLINElld:pubmed
pubmed-article:8020872pubmed:issn0767-3981lld:pubmed
pubmed-article:8020872pubmed:authorpubmed-author:SchallBBlld:pubmed
pubmed-article:8020872pubmed:authorpubmed-author:BigaudMMlld:pubmed
pubmed-article:8020872pubmed:authorpubmed-author:JauchM FMFlld:pubmed
pubmed-article:8020872pubmed:authorpubmed-author:HaussBBlld:pubmed
pubmed-article:8020872pubmed:authorpubmed-author:D'OrchymontHHlld:pubmed
pubmed-article:8020872pubmed:issnTypePrintlld:pubmed
pubmed-article:8020872pubmed:volume8lld:pubmed
pubmed-article:8020872pubmed:ownerNLMlld:pubmed
pubmed-article:8020872pubmed:authorsCompleteYlld:pubmed
pubmed-article:8020872pubmed:pagination155-61lld:pubmed
pubmed-article:8020872pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:meshHeadingpubmed-meshheading:8020872-...lld:pubmed
pubmed-article:8020872pubmed:year1994lld:pubmed
pubmed-article:8020872pubmed:articleTitleStructure activity relationship of phosphoramidon derivatives for in vivo endothelin-converting-enzyme inhibition.lld:pubmed
pubmed-article:8020872pubmed:affiliationMarion Merrell Dow Research Institute, Strasbourg, France.lld:pubmed
pubmed-article:8020872pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8020872pubmed:publicationTypeComparative Studylld:pubmed